5 Best Large-Cap Growth ETFs

In this article, we discuss 5 best large-cap growth ETFs. If you want to read our discussion on growth investing, head directly to 12 Best Large-Cap Growth ETFs. 

5. Vanguard Growth Index Fund ETF Shares (NYSE:VUG)

5-Year Share Price Performance as of May 3: 103.02%

Vanguard Growth Index Fund ETF Shares (NYSE:VUG) aims to replicate the CRSP US Large Cap Growth Index’s performance, offering a simple way to mirror the performance of numerous major American growth stocks. It utilizes a passively managed, full-replication strategy. Vanguard Growth Index Fund ETF Shares (NYSE:VUG) was founded on January 26, 2004. The ETF’s expense ratio has remained 0.04% since April 28, 2023. As of March 31, 2024, Vanguard Growth Index Fund ETF Shares (NYSE:VUG) holds 199 stocks in its portfolio, and the fund features net assets of $226.5 billion. VUG ranks 5th on our list of the best large-cap growth ETFs.

Pharma giant Eli Lilly and Company (NYSE:LLY) is one of the top holdings of Vanguard Growth Index Fund ETF Shares (NYSE:VUG). Eli Lilly and Company (NYSE:LLY) was part of 102 hedge fund portfolios at the end of the fourth quarter of 2023, same as the prior quarter. Ken Fisher’s Fisher Asset Management held the largest stake in the company, with 4.5 million shares worth $2.6 billion.

Aristotle Atlantic Core Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2023 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its top-selling drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment, Human pharmaceutical products.

Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase three assets, Orforglipron, an oral GLP-1 and retatrutide, a triple incretin agonist, which have the potential to expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond type 2 diabetes and obesity, potentially in the areas mentioned above of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.”